Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial.

Pettus J, Boeder SC, Christiansen MP, Denham DS, Bailey TS, Akturk HK, Klaff LJ, Rosenstock J, Cheng MHM, Bode BW, Bautista ED, Xu R, Yan H, Thai D, Garg SK, Klein S.

Open source

DOI: 10.1038/s41591-022-02011-x
Published: 2022-10-03
Container: Nat Med
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41591-022-02011-x,
  title = {Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial.},
  author = {Pettus J and  Boeder SC and  Christiansen MP and  Denham DS and  Bailey TS and  Akturk HK and  Klaff LJ and  Rosenstock J and  Cheng MHM and  Bode BW and  Bautista ED and  Xu R and  Yan H and  Thai D and  Garg SK and  Klein S.},
  year = {2022},
  journal = {Nat Med},
  doi = {10.1038/s41591-022-02011-x},
  url = {https://doi.org/10.1038/s41591-022-02011-x}
}

RIS

TY  - JOUR
TI  - Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial.
AU  - Pettus J
AU  -  Boeder SC
AU  -  Christiansen MP
AU  -  Denham DS
AU  -  Bailey TS
AU  -  Akturk HK
AU  -  Klaff LJ
AU  -  Rosenstock J
AU  -  Cheng MHM
AU  -  Bode BW
AU  -  Bautista ED
AU  -  Xu R
AU  -  Yan H
AU  -  Thai D
AU  -  Garg SK
AU  -  Klein S.
PY  - 2022
JO  - Nat Med
DO  - 10.1038/s41591-022-02011-x
UR  - https://doi.org/10.1038/s41591-022-02011-x
ER  -

APA

J, P., SC, B., MP, C., DS, D., TS, B., HK, A., LJ, K., J, R., MHM, C., BW, B., ED, B., R, X., H, Y., D, T., SK, G., & S., K. (2022). Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial.. Nat Med. https://doi.org/10.1038/s41591-022-02011-x

Source records

europe-pmc · retrieved 2026-09-27T04:03:12.334Z